Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

Last updated: August 12, 2024
Sponsor: Erchonia Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neurologic Disorders

Treatment

Erchonia® EVRL™

Placebo Laser

Clinical Study ID

NCT05291975
R-DPN-HOME
  • Ages > 18
  • All Genders

Study Summary

The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic neuropathy foot pain in individuals diagnosed with diabetic neuropathy by a suitably qualified and licensed health professional.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Previously diagnosed with diabetes induced peripheral neuropathy by a suitablyqualified and licensed health professional within the past 6 months

  • Over the age of 18 years of age

  • Able to read and write English.

  • Constant feet pain on-going over at least the past 3 months.

  • If using analgesics (pain medication), you must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14days prior to enrollment; and willing and able to not have planned upward dosetitration of analgesics during the study period. You may elect to decrease analgesicuse during the study. Cannabis prescribed for medicinal purposes would qualify as ananalgesic in this context.

  • Willing and able to refrain from engaging in any non-study procedure therapies forthe management of foot pain throughout the course of study participation, includingconventional therapies such as physical therapy, occupational therapy and hot orcold packs, as well as alternative therapies such as chiropractic care andacupuncture.

  • Agrees to refrain from taking a dosage of analgesic (pain medication) for at least 6hours before a scheduled VAS foot pain rating is to be recorded.

  • Subjects' degree of foot pain on the 0-100 VAS, with "0" being no pain and "100"being worst pain imaginable, is 50 or greater.

Exclusion

Exclusion Criteria:

  • Pregnant or think you might be pregnant.

  • Open wounds (sores, cuts, ulcers, etc) around the feet

  • Cancerous growths around the feet

  • Difficulty with hand dexterity sufficient to impact ability to administer treatmentswith the laser such as from severe arthritis in the hands, Multiple Sclerosis,Cerebral Palsy, Parkinson's Disease, Huntington's Disease, etc.

Study Design

Total Participants: 64
Treatment Group(s): 2
Primary Treatment: Erchonia® EVRL™
Phase:
Study Start date:
February 17, 2022
Estimated Completion Date:
December 17, 2024

Study Description

Human Factors Validation Testing will initially be conducted to valuate a lay person's ability to understand and apply as applicable the information contained in the EVRL™ Use Device Proper Use Reference Guide, and device packaging and labeling materials to correctly, safely, and successfully activate and operate the EVRL™ to administer the treatment; and to identify any and all use difficulties, problems and errors, including those pertaining to critical tasks and close calls demonstrated by the lay person during device operation, and to subsequently mitigate each identified instance of use error through device and/or materials modification, and to subsequently evaluate the effectiveness of each modification, as applicable

Phase Two will commence following the successful completion of Phase One. Phase Two comprises the performance of a double-blind, randomized, placebo-controlled, clinical study of the efficacy of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Sponsor), for prescription home use application in providing temporary relief of diabetic peripheral neuropathy foot pain.

Connect with a study center

  • CiC Foot & Ankle

    Phoenix, Arizona 85028
    United States

    Completed

  • Laser Chiropractic

    West Covina, California 91790
    United States

    Active - Recruiting

  • Cesar A. Lara M.D. Weight Loss & Wellness

    Dunedin, Florida 34698
    United States

    Completed

  • FRANCO & CO Podiatric Medicine & Surgery

    Miramar, Florida 33025
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.